Abstract
Inhibitors of Staphylococcus aureus biotin protein ligase (SaBPL) are generated by replacing the acyl phosphate group of biotinyl-5'-AMP with either a 1,2,3-triazole (see 5/10a/10b) or a 1,2,4-oxadiazole (see 7) bioisostere. Importantly, the inhibitors are inactive against the human BPL. The nature of the 5-substituent in the component benzoxazolone of the optimum 1,2,3-triazole series is critical to activity, where this group binds in the ATP binding pocket of the enzyme.
Keywords:
Antibiotics; Bioisosteres; Drug design; Inhibitors; Ligases.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Bacterial Proteins / antagonists & inhibitors*
-
Bacterial Proteins / metabolism
-
Biotin / antagonists & inhibitors*
-
Biotin / metabolism
-
Crystallography, X-Ray
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Heterocyclic Compounds / chemical synthesis
-
Heterocyclic Compounds / chemistry
-
Heterocyclic Compounds / pharmacology*
-
Humans
-
Ligases / antagonists & inhibitors*
-
Ligases / metabolism
-
Models, Molecular
-
Molecular Structure
-
Organophosphates / chemical synthesis
-
Organophosphates / chemistry
-
Organophosphates / pharmacology*
-
Staphylococcus aureus / enzymology
Substances
-
Bacterial Proteins
-
Enzyme Inhibitors
-
Heterocyclic Compounds
-
Organophosphates
-
Biotin
-
Ligases